510(k) · Cleared
ClearedBlastGen
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Origio A/S · MQL Media, Reproductive
Cleared on Feb 29, 2016 as substantially equivalent to K133387 (Origio A/S, 2014) after a 147-day review. Its family tree reaches back 3 generations to 2001.
- Decided
- Feb 29, 2016
- Review
- 147 days
- Class
- Class II
- Product code
- MQL
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 3 generations to K003156 (2001). No later device cites it as a predicate yet.
- Root · 3 generations backK003156 Blastassist SystemMedicult A/S · 2001
- 2 generations backK080172 Blastassist Without Phenol Red, Model Ref 1215, Blastassist with…Medicult A/S · 2008
- 1 generation backK133387 Origio (R) Sequential Blast TM; Origio (R) Sequential Blast TM with…Origio A/S · 2014
- This deviceK152932 BlastGenOrigio A/S · 2016
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −3 | K003156 | Blastassist System | Medicult A/S | 2001 | — |
| −2 | K080172 | Blastassist Without Phenol Red, Model Ref 1215, Blastassist with Phenol Red… | Medicult A/S | 2008 | — |
| −1 | K133387 | Origio (R) Sequential Blast TM; Origio (R) Sequential Blast TM with Phenol Red | Origio A/S | 2014 | — |
| 0 (this device) | K152932 | BlastGen | Origio A/S | 2016 | — |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in MQL? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new MQL device
- #1 K251305 Ultra-Fast Vitri; Ultra-Fast Warmscore 14.4 · 6 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K133387 | Origio (R) Sequential Blast TM; Origio (R) Sequential Blast TM with Phenol RedSummary page 4…fication name: Reproductive media and supplements (21 CFR 884.6180, Product Code MQL) Predicate Devices: ORIGIO® Sequential Blast™ (Cat. No. 8305) (K133387) Device Description: BlastGen™ is based on ORIGIO® Sequential Blast™ (K133387) with the supplement of Leukine (Sargramostim) gr… | 2014 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 15 years and passes through 2 companies; a new generation was cleared every 5.4 years on median.
- None of the 3 ancestors has a recall.
How does its category compare?
All MQL devicesMQL Media, Reproductive: FDA decisions, review times, recalls and adverse event reports over 20 years. 2016, this device’s year, is highlighted.
FDA decisions per year · MQL
9in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · MQL
225in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · MQL
1in 2023
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · MQL
3in 2025
MAUDE reports naming product code MQL, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 3 | 212 | 0 | 0 |
| 2008 | 12 | 151 | 0 | 0 |
| 2009 | 2 | — | 0 | 0 |
| 2010 | 6 | 235 | 0 | 0 |
| 2011 | 1 | — | 0 | 0 |
| 2012 | 5 | 253 | 1 | 1 |
| 2013 | 0 | — | 0 | 2 |
| 2014 | 5 | 142 | 0 | 3 |
| 2015 | 7 | 87 | 0 | 0 |
| 2016 | 12 | 170 | 0 | 2 |
| 2017 | 10 | 113 | 0 | 0 |
| 2018 | 4 | 94 | 0 | 0 |
| 2019 | 6 | 170 | 0 | 0 |
| 2020 | 8 | 257 | 1 | 0 |
| 2021 | 1 | — | 2 | 0 |
| 2022 | 3 | 316 | 1 | 0 |
| 2023 | 5 | 199 | 1 | 1 |
| 2024 | 12 | 195 | 0 | 6 |
| 2025 | 9 | 225 | 0 | 3 |
| 2026 | 3 | 179 | 0 | — |
What is it indicated for?
BlastGen™ is for the culture of embryos from the 4-8 cell stage through to the blastocyst stage.
BlastGen™ can also be used for embryo transfer.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K152932 · printed Nov 6, 2026
Cite this page
510(k) Report. “K152932: BlastGen.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K152932
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026